Sensus Healthcare Appoints Larry Biscotti to its Board of Directors

Sensus Healthcare, Inc. (Nasdaq: SRTS), a leader in non-invasive medical treatments for both oncological and non-oncological skin conditions, has welcomed Larry Biscotti to its Board of Directors, effective immediately. His addition expands the board to six members, with four being independent directors. Mr. Biscotti brings over 25 years of executive experience in the medical device and healthcare technology industries, enhancing the board's expertise in commercial strategy and market expansion.

Currently, he serves as President, Imaging for the U.S. and Canada at GE HealthCare, overseeing its largest product segment. His substantial past roles at notable companies like Elekta, Varian Medical Systems, and Toshiba Medical contribute to a robust foundation in imaging, oncology, and radiation therapy technologies. Joe Sardano, Sensus Healthcare's Chairman and CEO, emphasized Biscotti’s impressive track record of leading multibillion-dollar operations, innovating cancer treatment technologies, and building successful global commercial teams. Sardano expressed confidence in Biscotti’s integrity and commitment to improving patient outcomes, aligning well with Sensus’ culture and mission.

In his own words, Biscotti expressed honor in joining Sensus Healthcare at a pivotal time when patient-centered, non-invasive treatments are increasingly vital. He noted that the company's dedication to innovation and clinical excellence resonates deeply with his professional values and experiences. Biscotti holds an MBA from Pepperdine University and a Bachelor of Science from Cornell University, alongside completion of Harvard Business School's Program for Leadership Development.

Sensus Healthcare continues to be a pioneer in non-invasive treatments for skin cancer and keloids, leveraging advanced technologies to provide effective, patient-centric care. For more details, visit www.sensushealthcare.com.

The recent appointment of Larry Biscotti to the Board of Directors at Sensus Healthcare (NASDAQ: SRTS) is a significant development for the company, which specializes in innovative, non-invasive treatments for skin conditions. Biscotti's extensive experience in the medical device and healthcare technology sectors is expected to enhance Sensus Healthcare's strategic direction and market execution.

Biscotti's background, particularly his role at GE HealthCare leading the Imaging segment for the U.S. and Canada, aligns well with Sensus Healthcare’s focus on advancing its superficial radiotherapy (SRT) technology. His history of driving commercial growth and launching imaging and oncology technologies positions him to provide invaluable insights as Sensus seeks to expand its market share and enhance its product offerings.

Investors may view this leadership change as a positive signal of Sensus's commitment to innovation and clinical excellence, essential traits in a rapidly evolving healthcare landscape. Biscotti's aim to support the company’s growth while improving patient outcomes could resonate well with investors looking for companies with a strong social impact focus.

Moreover, with four independent directors now on the board, Sensus is positioning itself for enhanced governance that may attract institutional investors who prioritize strong board oversight. This appointment may also stimulate investor confidence, particularly as the company continues to unveil its long-term strategic initiatives.

Given the increasing demand for patient-centered healthcare solutions, Sensus Healthcare is well-positioned for growth. Investors should keep an eye on any further developments from the board as they may provide critical insights into strategic initiatives and product innovations that will shape the company's future trajectory. Overall, Sensus Healthcare represents a compelling opportunity in the medical device sector, particularly with Biscotti on board to guide its continued evolution.